Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Drug Makers Concerned about Cost-Effective Assessments Used for NHI Price Cuts: Survey
November 28, 2016
- Shionogi Set to Go Global with Botulinum Toxin, Gets Rights from Tokushima Univ.
November 25, 2016
- CSL Behring to Enter Japanese Hemophilia Market with Idelvion
November 25, 2016
- MSD to Distribute Bayer’s Adempas from Next Year
November 25, 2016
- Ninlaro Earns Conditional Approval in Europe: Takeda
November 25, 2016
- Gynecologist Calls for Correct Understanding of Hormonal Products
November 24, 2016
- 27 Japan Drug Makers Eke Out Profit despite Logging Lower Sales on FX, Price Cuts: Jiho Tally
November 24, 2016
- Empliciti “Extremely Promising” in the Treatment of Multiple Myeloma: Hematologist
November 24, 2016
- Fujifilm Hooks Up with China Resources in Healthcare
November 22, 2016
- Taltz Finally Makes it to Japan Market after Pricing Flap
November 22, 2016
- Empliciti, Batch of Other Drugs Go on Sale in Japan
November 21, 2016
- 3 Japan Generic Majors See Subdued Sales Rise in April-September
November 21, 2016
- Invalidation Ruling for Evista Upheld: Sawai
November 21, 2016
- Eisai’s BACE Inhibitor Gets FDA’s Fast-Track Status
November 21, 2016
- AbbVie to File for Dual Hep C Treatments Offering Shorter Treatment Time than Harvoni, Sovaldi
November 18, 2016
- Sanofi Begins Praluent Post-Marketing Study in Japanese ACS Patients
November 17, 2016
- Sanofi Japan Looks to Launch 20-Plus Products by 2020: New Chief
November 17, 2016
- Ono Braces for “Unexpected Negative Impact” from Price Cut, Calls for Stable Rules
November 17, 2016
- Japan CNS Market to Reach 648.7 Billion Yen in 2024: Fuji Keizai
November 17, 2016
- First DOAC Antidote to Hit Japan Market This Month
November 16, 2016
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…